Profil bibliographique

Jeffrey Kraft

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

34Publications signalées

1557Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

Treatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorAcute Myeloid Leukemia ResearchPI3K/AKT/mTOR signaling in cancerChronic Lymphocytic Leukemia Research

Les publications récentes

2026 article OpenAlex

FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Elaine Chang, Flora Mulkey, Vicky Hsu et autres

us (code pays fourni par la source)

0 citations Clinical Cancer Research

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S1 from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Sonia Singh, Diana Bradford, Somak Chatterjee, Xiaoxue Li et autres

1 citation

Accès ouvert 2025 other OpenAlex

Data from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Sonia Singh, Diana Bradford, Somak Chatterjee, Xiaoxue Li et autres

0 citations

Accès ouvert 2025 article OpenAlex

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Sonia Singh, Diana Bradford, Somak Chatterjee, Xiaoxue Li et autres

us (code pays fourni par la source)

24 citations Clinical Cancer Research

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S1 from FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Ashley Woods, Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S2 from FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Ashley Woods, Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke et autres

0 citations

Accès ouvert 2025 other OpenAlex

Data from FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Ashley Woods, Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke et autres

0 citations

Accès ouvert 2024 article OpenAlex

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Ashley Woods, Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke et autres

us (code pays fourni par la source)

12 citations Clinical Cancer Research

Accès ouvert 2024 article OpenAlex

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Brian L. Heiss, Elaine Chang, Xin Gao, Tien M. Truong et autres

us, jp, gb (code pays fourni par la source)

27 citations Journal of Clinical Oncology

Accès ouvert 2024 other OpenAlex

Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Sonia Singh, Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani et autres

1 citation

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Sonia Singh, Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Sonia Singh, Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.